Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis
Advanced Science · 2025
DOI: 10.1002/advs.202508613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xiaoke Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medical Oncology, Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu ROAD, Harbin, 150086, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, NF-kappa B, Neovascularization, Pathologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Open Funds of State Key Laboratory of Oncology in South China, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Clathrin light chain B (CLTB) is one of the three light chain subunits of the clathrin complex. This study aims to elucidate the role of CLTB in the pathogenesis of hepatocellular carcinoma (HCC) and its clinical implications. Clinical and bioinformatic analyses reveal marked CLTB overexpression in HCC tissues. Genetic silencing of CLTB suppresses HCC cell proliferation, migration, and invasion, whereas its overexpression exacerbates malignant phenotypes. Mechanistically, CLTB activates NF‐κB signaling to upregulate PCNA clamp‐associated factor (PCLAF), thereby promoting small extracellular vesicle (sEV) uptake. Given that clathrin‐mediated endocytosis is the key mechanism for sEV uptake, this study further investigated the functional implications of CLTB‐enriched sEVs in tumor vascular remodeling. sEV‐CLTB promotes endothelial angiogenesis, disrupts vascular integrity, and induces pulmonary vascular leakage by binding SH3 domain‐containing kinase‐binding protein 1 (SH3KBP1) and then inhibiting SH3KBP1 ubiquitination degradation. In patient‐derived xenograft (PDX) models, combined therapy of clathrin inhibitor (chlorpromazine) or SH3KBP1 silencing with sorafenib suppresses tumor growth and reduces microvascular density. This study demonstrates that CLTB promotes HCC progression through the NF‐κB–PCLAF signaling axis and sEV‐mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medical Oncology, Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu ROAD, Harbin, 150086, P. R. China.
- Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu ROAD, Harbin, 150086, P. R. China.
- Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu ROAD, Harbin, 150086, P. R. China.
- State Key Laboratory of Oncology in South China, Cancer Center of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
- Department of Pathology, The Li Ka Shing Faculty of Medicine at The University of Hong Kong, Hong Kong, 999077, P. R. China.
Förderung
- National Natural Science Foundation of China
- Open Funds of State Key Laboratory of Oncology in South China
- Beijing Xisike Clinical Oncology Research Foundation
- Beijing Science and Technology Innovation Medical Development Foundation
- Anhui Engineering Technology Research Center of Biochemical Pharmaceutical, Bengbu Medical University
- Opening Project of the Scientific and Technological Innovation Major Base of Guangxi
- Education Department of Guangxi Zhuang Autonomous Region
- Key Laboratory of Human Development and Disease Research, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region
Zitieren
APA
Sun, X., Guo, J., Zhao, N., Cui, G., Bai, Y., Ding, M., Xu, Y., & Yang, Y. (2025). Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis. Advanced Science. https://doi.org/10.1002/advs.202508613
Vancouver
Sun X, Guo J, Zhao N, Cui G, Bai Y, Ding M, et al. Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis. Advanced Science. 2025. doi:10.1002/advs.202508613
BibTeX
@article{Sun2025,
author = {Sun, Xiaoke and Guo, Junchen and Zhao, Ning and Cui, Guanghua and Bai, Yun and Ding, Meijuan and Xu, Yi and Yang, Yu},
title = {Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202508613}
}
EUVIMED